

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

**華康生物醫學控股有限公司**

*(Incorporated in Cayman Islands with limited liability)*

**(Stock Code: 8622)**

### **INSIDE INFORMATION DISPOSAL OF SHARES BY A CONTROLLING SHAREHOLDER**

This announcement is made by Huakang Biomedical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM (the “**GEM Listing Rules**”) of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (“**Directors**”) of the Company has been informed by Crystal Grant Limited. (“**Crystal Grant**”), a controlling shareholder (as defined in the GEM Listing Rules) of the Company, that on 9 January 2024, Crystal Grant had dispose of 5,360,000 issued shares of the Company on open market (the “**Disposal**”), representing 1.28% of the total number of issued shares of the Company (the “**Share(s)**”) as at the date of this announcement, at the average price of approximately HKD0.152 per Share, through on-market transactions on the trading platform of Stock Exchange.

The Disposal was made on the open market. To the best of the Company’s knowledge, information and belief, having made all reasonable enquiries, the Company is not aware of the identities of the counterparties of the Disposal or of their respective principal business activities.

Immediately after the Disposal, the number of Shares held by Crystal Grant decreased from 144,032,000 Shares (representing approximately 34.42% of the total issued share capital of the Company) to 138,672,000 Shares (representing approximately 33.14% of the total issued share capital of the Company).

As at the date of this announcement, Crystal Grant is one of the Controlling Shareholders by reason of the Acting-in-concert Confirmation (“**Confirmation**”) dated on 16 November 2017 entered into by Mr. Zhang Shuguang (“**Mr. Zhang**”) (the sole shareholder of Crystal Grant) and Mr. Chang Yim Yang (“**Mr. Chang**”) (the sole shareholder of Ever Charming Inc. (“**Ever Charming**”)) (please refer to the section headed “History and Reorganisation” in our prospectus dated 30 November 2018 for further details), Mr. Zhang and Mr. Chang were entitled to exercise more than 30% of the voting rights at the general meeting of the Company and were collectively considered as controlling shareholders of the Company.

The Board does not expect that the Disposal will have any material adverse effect on the operations of the Group.

**Shareholders and potential investors of the Company are urged to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Shuguang**  
Chairman and Executive Director

Hong Kong, 10 January 2024

*As at the date of this announcement, the Executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary, Mr. Chan Kin Sang and Ms. Chow Ching Man.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*